Document text
ACIP COVID -19 Vaccines Work Group
Robert Schechter, MD
COVID -19 ACIP Work Group Chair
Advisory Committee on Immunization Practices Meeting
October 23, 2024National Center for Immunization and Respiratory Diseases
•To protect against COVID -19 disease, caused by SARS -CoV-2, ACIP recommended at its June 2024
meeting the 2024 –2025 COVID -19 vaccines, as authorized or approved by FDA:
-Moderna COVID -19 vaccine in persons ≥6 months
-Pfizer -BioNTech COVID -19 vaccine in persons ≥6 months
-Novavax COVID -19 vaccine in persons ≥ 12 years*
•Everyone aged 5 years and older should get 1 dose of a 2024 –2025 COVID -19 vaccine
•Children aged 6 months– 4 years need multiple doses of COVID- 19 vaccines to be up to date,
including at least 1 dose of 2024 –2025 COVID -19 vaccine
•People who are moderately or severely immune compromised may receive additional doses of
2024 –2025 COVID -19 vaccines under shared clinical decision making
•No recommendation for additional doses of 2024 –2025 COVID -19 vaccine for older adultsCurrent 2024– 2025 COVID -19 vaccine recommendations
*People who are previously unvaccinated for COVID -19 and are receiving Novavax should complete a 2 -dose initial series
•To protect against COVID -19 disease, caused by SARS -CoV-2, ACIP recommended at its June 2024
meeting the 2024 –2025 COVID -19 vaccines, as authorized or approved by FDA:
-Moderna COVID -19 vaccine in persons ≥6 months
-Pfizer -BioNTech COVID -19 vaccine in persons ≥6 months
-Novavax COVID -19 vaccine in persons ≥ 12 years*
•Everyone aged 5 years and older should get 1 dose of a 2024 –2025 COVID -19 vaccine
•Children aged 6 months– 4 years need multiple doses of COVID- 19 vaccines to be up to date,
including at least 1 dose of 2024 –2025 COVID -19 vaccine
•People who are moderately or severely immune compromised may receive additional doses of
2024 –2025 COVID -19 vaccines under shared clinical decision making
•No recommendation for additional doses of 2024 –2025 COVID -19 vaccine for older adultsCurrent 2024– 2025 COVID -19 vaccine recommendations
*People who are previously unvaccinated for COVID -19 and are receiving Novavax should complete a 2 -dose initial series
ACIP COVID -19 Work Group Meeting Review
July – October 2024
•Seasonality of SARS- CoV-2
•Epidemiology of COVID -19
in older adults and persons
with immunocompromise
•SARS -CoV-2 variant updates
•Vaccine safety updateRegarding additional doses of COVID -19 vaccine:
•Vaccine effectiveness
•Uptake and intent survey data
•Economic analyses
•Implementation
Agenda: October 23, 2024
Introduction Dr. Robert Schechter (ACIP, WG Chair)
COVID -19 vaccine uptake and implementation Dr. Georgina Peacock (CDC/NCIRD)
COVID -19 epidemiology Dr. Christopher Taylor (CDC/NCIRD)
COVID -19 vaccine effectiveness Dr. Ruth Link -Gelles (CDC/NCIRD)
Economic analysis of an additional dose of the
2024 -2025 COVID -19 vaccineDr. Lisa Prosser (University of Michigan)
Evidence to Recommendations Ms. Lauren Roper (CDC/NCIRD)
Clinical considerations Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)
Vote Ms. Lauren Roper (CDC/NCIRD)
In addition to previously recommended 2024 –2025 vaccination:
•ACIP recommends a second dose* of 2024– 2025 COVID -19 vaccine for adults ages
≥65 years
•ACIP recommends a second dose** of 2024– 2025 COVID -19 vaccine for people
ages 6 months –64 years who are moderately or severely immunocompromised
•ACIP recommends additional doses (i.e., 3 or more doses) of 2024– 2025 COVID -19
vaccine for people ages ≥6 months who are moderately or severely
immunocompromised under shared clinical decision makingVote language
*If previously unvaccinated and receiving Novavax, 2 doses are recommended as initial vaccination series followed by a third dose of any age -
appropriate 2024 -2025 COVID -19vaccine 6 months (minimum interval 2 months) after second dose.
**If previously unvaccinated or receiving initial vaccination series, at least 2 doses of 2024 –2025 vaccine are recommended, and depending on
vaccination history more may be needed. This additional 2024– 2025 vaccine dose is recommended 6 months (minimum interval 2 month s) after
completion of initial vaccination series.
•During October 2023– April 2024, adults aged ≥65 years accounted for 70%
of all COVID- 19–associated hospitalizations among adults.
-Most hospitalized adults had multiple underlying medical conditions.
-12% had received the recommended COVID -19 2023– 2024 formula vaccine.
•During October 2022– April 2024, COVID- 19–associated hospitalization rates
in infants aged <6 months were similar to those in adults aged 65 –74 years.
-The percentage of hospitalized infants whose mothers had been vaccinated
during pregnancy was 18% during October 2022 –September 2023 and decreased
to <5% during October 2023 –April 2024.Recent COVID -NET Reports Describe
Low Immunization Rates in Hospitalized, High- Risk Populations
www.cdc.gov/mmwr/volumes/73/wr/mm7339a2.htm?s_cid=mm7339a2_w
www.cdc.gov/mmwr/volumes/73/wr/mm7338a1.htm?s_cid=mm7338a1_w
Work Group members
ACIP members
•Robert Schechter (chair)
•Noel Brewer
•Oliver Brooks
•George Kuchel
•Keipp Talbot
Ex-officio/government members
•BARDA: Christine Oshansky
•CDC: Alan Lam
•FDA: Adam Spanier, Rachel Zhang
•IHS: Uzo Chukwuma
•NIH: Chris Roberts
CDC co -Leads
•Lakshmi Panagiotakopoulos
•Lauren RoperLiaisons
•AAFP: Jonathan Temte
•AAP: Sean O’Leary
•ACOG: Naima Joseph (primary),
Laura Riley (alternate)
•ACP: Jason Goldman
•AGS: Ken Schmader
•AIM: Heather Roth
•AMA: Sandra Fryhofer
•ANA: Ruth Francis
•APhA: Richard Dang
•ASTHO: Marcus Plescia
•CSTE: Paul Cieslak, Christine Hahn
•IDSA: James McAuley Liaisons, cont’d
•NACCHO: Matt Zahn
•NACI: Eva Wong (primary), Matthew Tunis (alternate)
•NFID: Robert Hopkins (primary), Bill Schaffner (alternate)
•SHEA: Preeti Mehrotra (primary),
Marci Drees (alternate)
Consultants
•Ed Belongia
•Hank Bernstein
•Matthew Daley
•Kathy Edwards
•Lisa Jackson•Dayna Matthew
•Jennifer Nelson
•Stanley Perlman
•Peter Szilagyi
CDC participants
•Amadea Britton
•Mary Chamberland
•Fatimah Dawood
•Jonathan Duffy
•Katherine Fleming -Dutra
•Kristen Folsom
•Julianne Gee
•Monica Godfrey
•Susan Goldstein
•Lisa Grohskopf
•Aron Hall
•Elisha Hall
•Demorah Hayes•Suzanne Heitfeld
•Rita Helfand
•Michele Hlavsa
•Jefferson Jones
•Ruth Link -Gelles
•Jessica MacNeil
•Josephine Mak
•Seth Abram Meador
•Michael Melgar
•Sarah Meyer
•Noelle -Angelique Molinari
•Danielle Moulia
•Ismael Ortega -Sanchez•Manisha Patel
•Amanda Payne
•Jamison Pike
•Hannah Rosenblum
•Sierra Scarbrough
•John Su
•Diya Surie
•Natalie Thornburg
•David Wentworth
•Melinda Wharton
•Trang Wisard
•JoEllen Wolicki
For more information, contact CDC
1-800- CDC -INFO (232- 4636)
TTY: 1 -888- 232- 6348 cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.